News | 17 January 2013
Cytos Biotechnology Ltd, a public biopharmaceutical company focused on the development of targeted immunotherapies, has provided an update on the phase II b clinical trial with its lead product candidate, CYT003, in allergic asthma. The clinical trial ...
Click on the link to read the full article at pharmabiz.com
(This link will open in a new window)